A citation-based method for searching scientific literature

Sebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, Jeremy Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohé, Delvys Rodriguez-Abreu, Diana S Y Abdulla, Helge Bischoff, Christian Brandts, Enric Carcereny, Jesús Corral, Anne-Marie C Dingemans, Eva Pereira, Jana Fassunke, Rieke N Fischer, Masyar Gardizi, Lukas Heukamp, Amelia Insa, Anna Kron, Roopika Menon, Thorsten Persigehl, Martin Reck, Richard Riedel, Sacha I Rothschild, Andreas H Scheel, Matthias Scheffler, Petra Schmalz, Egbert F Smit, Meike Limburg, Mariano Provencio, Niki Karachaliou, Sabine Merkelbach-Bruse, Martin Hellmich, Lucia Nogova, Reinhard Büttner, Rafael Rosell, Jürgen Wolf. J Thorac Oncol 2019
Times Cited: 44



Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Shun Lu, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung-Ju Ahn, Toshiaki Takahashi, Takeharu Yamanaka, Allison Kemner, Debasish Roychowdhury, Jolanda Paolini, Tiziana Usari, Keith D Wilner, Koichi Goto. J Clin Oncol 2018
Times Cited: 147




List of shared articles



Times cited

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
Jessica J Lin, Noura J Choudhury, Satoshi Yoda, Viola W Zhu, Ted W Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R Digumarthy, Charlotte Lee, Andrew Do,[...]. Clin Cancer Res 2021
12

Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2022
1

The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Barbara Melosky, Paul Wheatley-Price, Rosalyn A Juergens, Adrian Sacher, Natasha B Leighl, Ming-Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, Paul B Card,[...]. Lung Cancer 2021
12


ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
37

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Esther Conde, Susana Hernandez, Rebeca Martinez, Barbara Angulo, Javier De Castro, Ana Collazo-Lorduy, Beatriz Jimenez, Alfonso Muriel, Jose Luis Mate, Teresa Moran,[...]. J Thorac Oncol 2019
35

Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Haiyan Xu, Quan Zhang, Li Liang, Junling Li, Zhefeng Liu, Weihua Li, Lu Yang, Guangjian Yang, Fei Xu, Jianming Ying,[...]. Cancer Med 2020
8

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Kartik Sehgal, Andrew J Piper-Vallillo, Hollis Viray, Adeel M Khan, Deepa Rangachari, Daniel B Costa. Precis Cancer Med 2020
11

Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria. Trends Cancer 2021
4

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Yongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Sai-Hong Ignatius Ou,[...]. BMC Med 2021
3

Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion.
Xuehua Xie, Mengxing You, Erhong Meng, Shunyou Wang, Beifang Niu, Weiming Huang. J Cancer Res Clin Oncol 2022
0

Entrectinib for ROS1-rearranged non-small cell lung cancer after crizotinib-induced interstitial lung disease: A case report.
Mai Tanimura, Nobutaka Kataoka, Yusuke Kunimatsu, Rei Tsutsumi, Izumi Sato, Takayuki Nakano, Keiko Tanimura, Takayuki Takeda. Respirol Case Rep 2021
1

Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Andrea Sartore-Bianchi, Elio Gregory Pizzutilo, Giovanna Marrapese, Federica Tosi, Giulio Cerea, Salvatore Siena. Expert Rev Anticancer Ther 2020
10

How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged disease.
Lorenza Landi, Federico Cappuzzo. Transl Lung Cancer Res 2020
3

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
15

Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report.
Konstantinos Christofyllakis, Ana Raquel Monteiro, Onur Cetin, Igor Age Kos, Alastair Greystoke, Andrea Luciani. J Geriatr Oncol 2022
0

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort.
Amanda J W Gibson, Adrian Box, Winson Y Cheung, Michelle L Dean, Anifat A Elegbede, Desiree Hao, Aliyah Pabani, Randeep Sangha, Dafydd Gwyn Bebb. Curr Oncol 2022
0

Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report.
Yun Shu, Hui Li, Hongjuan Shang, Jun Chen, Xiaoxing Su, Wei Le, Yan Lei, Liming Tao, Cailiang Zou, Wendy Wu. Onco Targets Ther 2020
2

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies.
Alessandro Russo, Andrés F Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo. Transl Lung Cancer Res 2020
5

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Andrew G Robinson, Sarah Temin, Sherman Baker, Julie R Brahmer, Peter M Ellis, Laurie E Gaspar, Rami Y Haddad, Paul J Hesketh, Dharamvir Jain,[...]. J Clin Oncol 2021
64

Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines.
F Passiglia, S Pilotto, F Facchinetti, L Bertolaccini, M Del Re, R Ferrara, T Franchina, U Malapelle, J Menis, A Passaro,[...]. Crit Rev Oncol Hematol 2020
30

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations.
Giorgia Guaitoli, Federica Bertolini, Stefania Bettelli, Samantha Manfredini, Michela Maur, Lucia Trudu, Beatrice Aramini, Valentina Masciale, Giulia Grisendi, Massimo Dominici,[...]. Int J Mol Sci 2021
1

Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib.
Francesco Facchinetti, Antonin Levy, Samy Ammari, Charles Naltet, Pernelle Lavaud, Mihaela Aldea, Damien Vasseur, David Planchard, Benjamin Besse. Cancer Manag Res 2021
2

ROS1 Targeted Therapies: Current Status.
Christine M Azelby, Mandy R Sakamoto, Daniel W Bowles. Curr Oncol Rep 2021
5


Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis.
Huy Gia Vuong, Thu Quynh Nguyen, Hoang Cong Nguyen, Phuoc Truong Nguyen, An Thi Nhat Ho, Lewis Hassell. Target Oncol 2020
9


Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
3

ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
Jesse Elliott, Zemin Bai, Shu-Ching Hsieh, Shannon E Kelly, Li Chen, Becky Skidmore, Said Yousef, Carine Zheng, David J Stewart, George A Wells. PLoS One 2020
24

Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data.
Gabriel Tremblay, Michael Groff, Laura Iadeluca, Patrick Daniele, Keith Wilner, Robin Wiltshire, Lauren Bartolome, Tiziana Usari, Joseph C Cappelleri, D Ross Camidge. Future Oncol 2022
0

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.
Sébastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier. Curr Oncol 2022
0